Looking Ahead to The Future of Ophthalmic Drug Delivery

• The Next Generation of Long-Acting Ocular Delivery: Next-generation targeted and minimally invasive delivery systems beyond Intravitreal Injections to extend ocular exposure and reduce treatment burden
• Precision and Repeatable Office-Based Therapy: Advancing non-viral vectors, ASOs, siRNA, and other platforms for precise, durable, and potentially repeatable ocular therapies
• Engineering Exposure, Not Just Dose: Integrating tissue targeting, PK/PD, biomarkers, and digital twins to optimize ocular exposure, therapeutic windows, and patient selection
• AI-Powered Drug Delivery: Leveraging AI to design delivery systems, predict tissue exposure, optimize formulations, and enable more personalized ocular therapies

Speakers: